{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:23:08Z","timestamp":1790479388940,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1053\/j.gastro.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T23:20:02Z","timestamp":1628637602000},"page":"1842-1852.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts"],"prefix":"10.1053","volume":"161","author":[{"given":"Bin","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuiqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Chong","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-776X","authenticated-orcid":false,"given":"Jinqiu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.08.005_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib2","doi-asserted-by":"crossref","first-page":"f6633","DOI":"10.1136\/bmj.f6633","article-title":"Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts","volume":"347","author":"Khalili","year":"2013","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.08.005_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.08.005_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/gutjnl-2017-314903","article-title":"Adherent-invasive Escherichia coli in inflammatory bowel disease","volume":"67","author":"Palmela","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib6","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S2468-1253(20)30267-3","article-title":"Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/gutjnl-2017-314352","article-title":"Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study","volume":"68","author":"Ortqvist","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.08.005_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.08.005_bib10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/gutjnl-2017-315306","article-title":"Proton pump inhibitor use associated with changes in gut microbiota composition","volume":"67","author":"Reveles","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jgh.12073","article-title":"Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease","volume":"28","author":"Fujimoto","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A\u00a0decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"63","author":"Machiels","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3164\/jcbn.17-78","article-title":"The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study","volume":"62","author":"Takagi","year":"2018","journal-title":"J\u00a0Clin Biochem Nutr"},{"key":"10.1053\/j.gastro.2021.08.005_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","article-title":"Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection","volume":"175","author":"McDonald","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2021.08.005_bib16","first-page":"489","article-title":"Proton pump inhibitors, H2 blocker use, and risk of inflammatory bowel disease in children","volume":"24","author":"Schwartz","year":"2019","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.08.005_bib17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.gastro.2020.05.011","article-title":"Dietary inflammatory potential and risk of crohn's disease and ulcerative colitis","volume":"159","author":"Lo","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.08.005_bib18","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.08.005_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","article-title":"Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis","volume":"10","author":"Deshpande","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/ajg.2012.196","article-title":"A\u00a0prospective study of cigarette smoking and the risk of inflammatory bowel disease in women","volume":"107","author":"Higuchi","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.08.005_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455008","article-title":"Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease","volume":"95","author":"Shah","year":"2017","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2021.08.005_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.2012.05173.x","article-title":"Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease","volume":"36","author":"Juillerat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.08.005_bib23","doi-asserted-by":"crossref","unstructured":"Lu TX, Dapas M, Lin E, et\u00a0al. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies [published online ahead of print December 17, 2020]. Gut https:\/\/doi.org\/10.1136\/gutjnl-2020-321609","DOI":"10.1136\/gutjnl-2020-321609"},{"key":"10.1053\/j.gastro.2021.08.005_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004836-199406000-00012","article-title":"Is omeprazole helpful in inflammatory bowel disease?","volume":"18","author":"Dickinson","year":"1994","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.08.005_bib25","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11605-013-2172-y","article-title":"Chronic use of PPI and H2 antagonists decreases the risk of pouchitis after IPAA for ulcerative colitis","volume":"17","author":"Poritz","year":"2013","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1053\/j.gastro.2021.08.005_bib26","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2105\/AJPH.2016.303338","article-title":"Origin, methods, and evolution of the three Nurses' Health Studies","volume":"106","author":"Bao","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1053\/j.gastro.2021.08.005_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1053\/j.gastro.2021.08.005_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/apt.14796","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies","volume":"48","author":"Tran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.08.005_bib29","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1136\/bmj.e372","article-title":"Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study","volume":"344","author":"Khalili","year":"2012","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.08.005_bib30","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.08.005_bib31","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.08.005_bib32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1136\/gutjnl-2011-301574","article-title":"Geographical variation and incidence of inflammatory bowel disease among US women","volume":"61","author":"Khalili","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.08.005_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ije\/23.5.991","article-title":"Reproducibility and validity of a self-administered physical activity questionnaire","volume":"23","author":"Wolf","year":"1994","journal-title":"Int J Epidemiol"},{"key":"10.1053\/j.gastro.2021.08.005_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010038","article-title":"Cross-sectional study of diet, physical activity, television viewing and sleep duration in 233,110 adults from the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes","volume":"6","author":"Cassidy","year":"2016","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2021.08.005_bib35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.08.005_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.08.005_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/microorganisms9020286","article-title":"Anti-acid drug treatment induces changes in the gut microbiome composition of hemodialysis patients","volume":"9","author":"Lin","year":"2021","journal-title":"Microorganisms"},{"key":"10.1053\/j.gastro.2021.08.005_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.08.005_bib39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.aam9949","article-title":"Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion","volume":"357","author":"Byndloss","year":"2017","journal-title":"Science"},{"key":"10.1053\/j.gastro.2021.08.005_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.chom.2016.03.004","article-title":"Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of Salmonella","volume":"19","author":"Rivera-Chavez","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2021.08.005_bib41","doi-asserted-by":"crossref","unstructured":"Gandhi T, Sharma A, Vyas N, et\u00a0al. Lansoprazole a proton pump inhibitor prevents ibd by reduction of oxidative stress and NO levels in the rat [published online ahead of print March 16, 2021]. Drug Res (Stuttg) https:\/\/doi.org\/10.1055\/a-1389-5499","DOI":"10.1055\/a-1389-5499"},{"key":"10.1053\/j.gastro.2021.08.005_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2036.2008.03699.x","article-title":"Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts","volume":"28","author":"De Jonge","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.08.005_bib43","first-page":"704","article-title":"Update on the incidence and prevalence of inflammatory bowel disease in the United States","volume":"12","author":"Loftus","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2021.08.005_bib44","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/ecco-jcc\/jjaa037","article-title":"A\u00a0Systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe","volume":"14","author":"Roberts","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.08.005_bib45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ibd.21719","article-title":"Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.08.005_bib46","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1136\/gutjnl-2017-315729","article-title":"Proton-pump inhibitors and increased gastric cancer risk: time-related biases","volume":"67","author":"Suissa","year":"2018","journal-title":"Gut"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T22:46:11Z","timestamp":1709765171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521033503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0016508521033503"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.08.005","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}